Industry Growth Insights published a new data on “Pulmonary Arterial Hypertension (PAH) Market”. The research report is titled “Pulmonary Arterial Hypertension (PAH) Market research by Types (Prostacyclin and Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5), By Applications (Hospital, Clinic), By Players/Companies Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer, Arena”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Pulmonary Arterial Hypertension (PAH) Market Research Report
By Type
Prostacyclin and Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5
By Application
Hospital, Clinic
By Companies
Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer, Arena
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
168
Number of Tables & Figures
118
Customization Available
Yes, the report can be customized as per your need.
 Industry Outlook.svg)
Global Pulmonary Arterial Hypertension (PAH) Market Report Segments:
The global Pulmonary Arterial Hypertension (PAH) market is segmented on the basis of:
Types
Prostacyclin and Prostacyclin Analogs, SGC Stimulators, ERA, PDE-5
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Actelion
- Gilead Sciences
- United Therapeutics
- GlaxoSmithKline
- Pfizer
- Bayer
- Arena
 Market Overview.svg)
Highlights of The Pulmonary Arterial Hypertension (PAH) Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prostacyclin and Prostacyclin Analogs
- SGC Stimulators
- ERA
- PDE-5
- By Application:
- Hospital
- Clinic
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Pulmonary Arterial Hypertension (PAH) Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Pulmonary arterial hypertension (PAH) is a condition in which the pressure inside the pulmonary arteries becomes too high. This can lead to shortness of breath, chest pain, and even death. PAH is most common in older adults but can also occur in people of any age.
Some of the major companies in the pulmonary arterial hypertension (pah) market are Actelion, Gilead Sciences, United Therapeutics, GlaxoSmithKline, Pfizer, Bayer, Arena.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Pulmonary Arterial Hypertension (PAH) Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Pulmonary Arterial Hypertension (PAH) Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Pulmonary Arterial Hypertension (PAH) Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Pulmonary Arterial Hypertension (PAH) Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Pulmonary Arterial Hypertension (PAH) Market Size & Forecast, 2018-2028
4.5.1 Pulmonary Arterial Hypertension (PAH) Market Size and Y-o-Y Growth
4.5.2 Pulmonary Arterial Hypertension (PAH) Market Absolute $ Opportunity
Chapter 5 Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Type
5.2.1 Prostacyclin and Prostacyclin Analogs
5.2.2 SGC Stimulators
5.2.3 ERA
5.2.4 PDE-5
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Clinic
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Pulmonary Arterial Hypertension (PAH) Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Pulmonary Arterial Hypertension (PAH) Analysis and Forecast
9.1 Introduction
9.2 North America Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Type
9.6.1 Prostacyclin and Prostacyclin Analogs
9.6.2 SGC Stimulators
9.6.3 ERA
9.6.4 PDE-5
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Clinic
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Pulmonary Arterial Hypertension (PAH) Analysis and Forecast
10.1 Introduction
10.2 Europe Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Type
10.6.1 Prostacyclin and Prostacyclin Analogs
10.6.2 SGC Stimulators
10.6.3 ERA
10.6.4 PDE-5
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Clinic
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Pulmonary Arterial Hypertension (PAH) Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Type
11.6.1 Prostacyclin and Prostacyclin Analogs
11.6.2 SGC Stimulators
11.6.3 ERA
11.6.4 PDE-5
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Clinic
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Pulmonary Arterial Hypertension (PAH) Analysis and Forecast
12.1 Introduction
12.2 Latin America Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Type
12.6.1 Prostacyclin and Prostacyclin Analogs
12.6.2 SGC Stimulators
12.6.3 ERA
12.6.4 PDE-5
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Clinic
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Pulmonary Arterial Hypertension (PAH) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Type
13.6.1 Prostacyclin and Prostacyclin Analogs
13.6.2 SGC Stimulators
13.6.3 ERA
13.6.4 PDE-5
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Pulmonary Arterial Hypertension (PAH) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Clinic
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Pulmonary Arterial Hypertension (PAH) Market: Competitive Dashboard
14.2 Global Pulmonary Arterial Hypertension (PAH) Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Actelion
14.3.2 Gilead Sciences
14.3.3 United Therapeutics
14.3.4 GlaxoSmithKline
14.3.5 Pfizer
14.3.6 Bayer
14.3.7 Arena
